Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 1595-1601

  Li, Yanliang ^a   Lyu, Zhongchuan ^b   Zhao, Lixin ^c   Cheng, Hong ^d   Zhu, Dongyuan ^a   Gao, Yongsheng ^a   Shang, Xiuwan ^e   Shi, Huaijie ^e,f  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c LIAOCHENG PEOPLE'S HOSPITAL   (China)

^d JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e Agriculture Bureau of Wendeng City   (China)

^f Rizhao Hospital of Traditional Medicine   (China)

Author keywords

Colorectal tumor; Diagnosis; MGMT; Prognosis

Indexed keywords

DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOMA; CARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; GENETICS; HUMAN; META ANALYSIS; PROGNOSIS; PROMOTER REGION;

ADENOMA; CARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; HUMANS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84930919869     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2752-9     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
2. 6-alkylguanine-DNA alkyltransferase. Pharmacol Ther. 1987;34:167–79.
3. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50:6119–29.
4. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307.
5. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, et al. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer. 2008;7:94.
6. 6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer. 2008;122:2429–36.
7. Nilsson TK, Lof-Ohlin ZM, Sun XF. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol. 2013;42:127–33.
8. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 2007;56:13–9.
9. Hibi K, Sakata M, Yokomizo K, Kitamura YH, Sakuraba K, et al. Methylation of the MGMT gene is frequently detected in advanced gastric carcinoma. Anticancer Res. 2009;29:5053–5.
10. Ma R, de Pennington N, Hofer M, Blesing C, Stacey R. Diagnostic and prognostic markers in gliomas—an update. Br J Neurosurg. 2013;27:311–5.
11. Marucci G, Morandi L, Mazzatenta D, Frank G, Pasquini E, et al. MGMT promoter methylation status in clival chordoma. J Neurooncol. 2014.
12. Coppede F, Migheli F, Lopomo A, Failli A, Legitimo A, et al. Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism. Epigenetics. 2014;9:621–33.
13. 6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut. 2010;59:1516–26.
14. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330–8.
15. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, et al. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Gene Chromosome Cancer. 2006;45:781–9.
16. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:686–700.
17. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189–99.
18. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC brain tumor group study 26951. J Clin Oncol. 2009;27:5881–6.
19. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26–32.
20. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 2001;61:827–30.
21. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11:5167–74.
22. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, et al. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760–8.
23. Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol. 2005;23:2318–24.
24. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control. 2011;22:301–9.
25. Zhang D, Wang Y, Bai Y, Ge Q, Qiao Y, et al. A novel method to quantify local CpG methylation density by regional methylation elongation assay on microarray. BMC Genomics. 2008;9:59.
26. Menigatti M, Truninger K, Gebbers JO, Marbet U, Marra G, et al. Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to DNA methylation at the hMLH1 and MGMT promoters. Oncogene. 2009;28:899–909.
27. Abouzeid HE, Kassem AM, Abdel Wahab AH, El-mezayen HA, Sharad H, et al. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumour Biol. 2011;32:845–52.
28. Chen SP, Chiu SC, Wu CC, Lin SZ, Kang JC, et al. The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients. Genet Test Mol Biomark. 2009;13:67–71.
29. Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol. 2010;17:1767–76.
30. Krtolica K, Krajnovic M, Usaj-Knezevic S, Babic D, Jovanovic D, et al. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol. 2007;13:1187–94.
31. Lee KH, Lee JS, Nam JH, Choi C, Lee MC, et al. Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence. Langenbecks Arch Surg. 2011;396:1017–26.
32. 6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep. 2013;40:3851–7.
33. 6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res. 2003;9:5306–12.
34. Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, et al. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS ONE. 2013;8:e60142.